Navigation Links
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
Date:5/27/2009

AMSTERDAM, May 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-021 for the treatment of acute intermittent porphyria (AIP).

Orphan Drug Designation for AIP entitles AMT to ten year market exclusivity in Europe following marketing approval for AMT-021 if this product candidate is the first new drug with a major medical benefit receiving marketing approval for the European Union. The designation also provides for special benefits, including research support, eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.

"We are proud to have received this Orphan Drug Designation for the treatment of acute intermittent porphyria," said Sander van Deventer, Chief Executive Officer of AMT. "This designation is an important step in the development of a treatment for this seriously debilitating and potentially lethal disease."

About Acute Intermittent Porphyria

Acute intermittent porphyria is a rare genetic disease in which mutations in the PBGD gene result in insufficient activity of a protein necessary for the synthesis of heme. This leads to an accumulation of toxic intermediate metabolites resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric, neurologic illnesses, and muscular weakness. Long-term consequences may be irreversible nerve damage, liver cancer and kidney failure. Acute porphyric attacks can be life-threatening.

AIP affects 1 per 10.000 people in the European Union.

Currently available therapies do not prevent the symptoms and consequences of acute porphyric attacks. AMT has demonstrated that its prod
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... CHESTER, Pa. , Sept. 19, 2014 /PRNewswire/ ... launched two new variable angle plating systems featuring ... technology, surgeons can adapt screw trajectory to match ... towards specific fragments of bone. The systems are ... Foot & Ankle Society (AOFAS) and the International ...
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... , Sept. 19, 2014  For Cloud ... drug design and development, partnering is an integral ... is to design new drugs and identify early ... partners to further their development. The company also ... To support this business model, Cloud Pharmaceuticals will ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... 2010 Zimmer Holdings, Inc. (NYSE: ZMH ... today announced it has acquired Sodem Diffusion S.A., the ... Geneva, Switzerland.  The company will be re-named Zimmer Surgical, ... in Dover, Ohio.   "Adding SoPlus,s innovative ...
... 22, 2010 Watson Pharmaceuticals (NYSE: WPI ) ... of a novel oral contraceptive product – the first and ... and 0.025 mg ethinyl estradiol in chewable form, with four ... daily, the product is proven effective in lowering ...
Cached Medicine Technology:Zimmer Announces Acquisition of SoPlus Orthopaedic Surgical Power Tools Company 2Watson Announces Novel Oral Contraceptive Approval 2Watson Announces Novel Oral Contraceptive Approval 3Watson Announces Novel Oral Contraceptive Approval 4
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... that bacterial pneumonia can raise your risk of heart problems, ... and kill heart cells, increasing the chances of heart failure, ... report. In mice, monkeys and human heart tissue, researchers ... and they tried a vaccine that might one day prevent ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 At ... the nonprofit Seafood Nutrition Partnership (SNP) announced the ... Heart Healthy: A Cardiovascular Risk Reduction Program for ... women understand and mitigate their risk of heart ... to Action, a plan for addressing significant global ...
(Date:9/22/2014)... Burbank, CA (PRWEB) September 22, 2014 ... social and mobile recruiting, announced today an ... talent management solutions for the healthcare industry. ... to TweetMyJobs’ suite of social recruiting solutions ... management software designed specifically for healthcare organizations. ...
(Date:9/22/2014)... MAINE AND BOSTON -- In a collaboration that ... advance cancer research and patient care and accelerate ... Beth Israel Deaconess Medical Center (BIDMC) have established ... institutions, presidents announced today. , A recently signed ... Center to establish a comprehensive relationship in the ...
(Date:9/22/2014)... NCPDP, the not-for-profit pharmacy standards development ... 2014 Educational Summit , “Improving the Infrastructure for ... 11, 2014 at the Hyatt Regency Indianapolis. Steven ... Technology, Office of the National Coordinator for Health ... takes place right before NCPDP’s Work Group Meetings, ...
Breaking Medicine News(10 mins):Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 2Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 2Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 3Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 4Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3Health News:NCPDP Educational Summit, Improving the Infrastructure for Continuity of Care, Features Keynote, Steven Posnack 2Health News:NCPDP Educational Summit, Improving the Infrastructure for Continuity of Care, Features Keynote, Steven Posnack 3
... Mary Bono Mack (CA-45) and Nita Lowey (NY-18) ... and well-being of American youth by reintroducing the ... The bipartisan legislation, broadly supported by such organizations ... cross-sector collaboration for improving the health of young ...
... (Nasdaq: MDTH ), (the "Company") a healthcare ... and treatment of cardiovascular disease, today announced that it has ... quarter ended March 31, 2009 and the filing of its ... as a result of an ongoing internal assessment by the ...
... nation,s leading cardioelectrophysiologists, has joined The Mount Sinai Medical Center as ... ... (Vocus)-- Vivek Y. Reddy, M.D., one of the nation,s leading cardioelectrophysiologists, ... of Electrophysiology Laboratories. His appointment becomes effective July 1., , ...
... C. Kolars, M.D., has been named the University ... for Education and Global Initiatives, effective June 1, pending the ... the Medical School,s lead for the oversight and expansion of ... James O. Woolliscroft , M.D., the medical school,s ...
... Fund now has within its reach the potential to ... meeting in Geneva, the Board of Directors of the ... Fund), today agreed to enhance the Fund,s response to ... prevent mother-to-child transmission of HIV (PMTCT), thereby opening the ...
... of the Clopidogrel Medco Outcomes Study presented today during SCAI,s ... may be reduced when taken concurrently with commonly used heartburn ... patients taking clopidogrel and a PPI experienced a: , ... 50% increase in the combined risk of hospitalization for heart ...
Cached Medicine News:Health News:Bono Mack, Lowey Introduce Bill To Improve the Health of Youth 2Health News:Vivek Y. Reddy, M.D., Joins The Mount Sinai Medical Center as Director of Electrophysiology Laboratories 2Health News:Vivek Y. Reddy, M.D., Joins The Mount Sinai Medical Center as Director of Electrophysiology Laboratories 3Health News:Joseph C. Kolars, M.D., to be U-M Medical School's First Senior Associate Dean for Education and Global Initiatives 2Health News:GAA Applauds Global Fund's Decision to Accelerate Support for Treatment Strategies to Prevent Mother-to-Child Transmission of HIV 2Health News:SCAI Statement on 'A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study' 2
... to 17 parameters from just 95 ... blood gases, as well as any ... metabolite parameters. Unique technology reduces to ... substances have on the accuracy of ...
... a sophisticated whole blood analysis system that ... also satisfying the stringent requirements of the ... contains all of the components of a ... the sampling unit, all of the sensors ...
... The Rapidlab 800 System is a ... key critical care whole blood parameters in ... modular design allows the basic blood gas ... to include electrolytes, metabolites and CO-oximetry in ...
This compact, easy-to-operate analyzer delivers basic blood gas, ISEs with direct measured total hemoglobin and saturated oxygen. Use it as a cost effective backup for the central lab or for remote p...
Medicine Products: